FoundationOne CDx is a comprehensive genomic profiling test that is tissue based. It is used to identify individuals diagnosed with ALK+ non-small-cell lung cancer (NSCLC) who will be eligible for…
Speakers: Viola Zhu, MD, PhD, University of California Irvine & Larissa, Patient Ambassador Join us to learn more about ALK+ non-small cell lung cancer (NSCLC) and ALUNBRIG (brigatinib) as a…
Speakers: Tarek Mekhail, MD, Advent Health Cancer Institute & Larissa, Patient Ambassador Join us to learn more about ALK+ non-small cell lung cancer (NSCLC) and ALUNBRIG (brigatinib) as a treatment…
Speakers: Shayma Kazmi, MD, RPh Cancer Treatment Center of America & Danielle, Patient Ambassador Join us to learn more about ALK+ non-small cell lung cancer (NSCLC) and ALUNBRIG (brigatinib) as…
Speakers: Jason A. Salganick, MD & Larissa C., Patient Ambassador Join us to learn more about ALK+ non-small cell lung cancer (NSCLC) and ALUNBRIG (brigatinib) as a treatment option for…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
